Physician profile
Michael J Oros
NPI 1720278914
$10,828.35
in general payments reported to CMS, 2019-2025
32 companies · $1,986 in 2025
The $1,986 reported for 2025 was more than what 88% of Addiction Psychiatry providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,473 · 2020: $962 · 2021: $969 · 2022: $1,822 · 2023: $1,858 · 2024: $1,759 · 2025: $1,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,403 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,402.81 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $1,545.96 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $1,071.98 | 2019-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $1,023.48 | 2019-2025 | Trintellix |
| Almatica Pharma LLC | $912.72 | 2021-2025 | Loreev Xr, Sertraline Hcl, Gralise |
| Bausch Health US, LLC | $871.20 | 2019-2025 | Aplenzin, Wellbutrin |
| Indivior INC. | $822.25 | 2019-2025 | Sublocade |
| Neurocrine Biosciences, INC. | $603.88 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $540.33 | 2022-2025 | Auvelity, Sunosi |
| Orexo US, INC. | $411.84 | 2019-2024 | Zubsolv |
| Lundbeck LLC | $357.81 | 2019-2025 | Rexulti, Brintellix |
| Alkermes, INC. | $334.31 | 2021-2025 | Vivitrol, Aristada, Vivitrol |
| Abbvie INC. | $322.67 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $285.21 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $270.16 | 2020-2025 | Caplyta |
| Janssen Scientific Affairs, LLC | $200.00 | 2024 | Spravato |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $183.76 | 2019-2020 | |
| Noven Therapeutics, LLC | $137.51 | 2021-2025 | Xelstrym, Secuado |
| Shire North American Group INC | $125.94 | 2019 | |
| Jazz Pharmaceuticals INC. | $120.61 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $118.45 | 2019-2020 | |
| Novo Nordisk INC | $96.62 | 2021-2023 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $90.90 | 2022-2023 | Austedo, Austedo Xr |
| Braeburn INC. | $76.57 | 2023-2024 | Brixadi |
| Ironshore Pharmaceuticals INC. | $51.10 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $50.49 | 2024-2025 | Qelbree |
| Merck Sharp & Dohme LLC | $49.24 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $42.25 | 2022-2024 | Quviviq |
| Avanir Pharmaceuticals, INC. | $33.14 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.98 | 2025 | Rejoyn |
| Corium, LLC | $24.75 | 2022 | |
| Neuronetics, INC. | $13.91 | 2022 | |
| Tris Pharma INC | $13.33 | 2023 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Oros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.